An Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose of MMV390048 in Adult Patients With Acute, Uncomplicated Plasmodium Vivax or Falciparum Malaria Monoinfection Over a 35 Day Period

Trial Profile

An Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose of MMV390048 in Adult Patients With Acute, Uncomplicated Plasmodium Vivax or Falciparum Malaria Monoinfection Over a 35 Day Period

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs MMV 390048 (Primary)
  • Indications Malaria
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 25 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 28 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
    • 19 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top